Clinical Trials | February 17, 2026
Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Subscribe To Our Newsletter & Stay Updated
